Advertisement

Pramipexole Dihydrochloride Tablets

[04 March 2016]

Products Affected - Description

Pramipexole Dihydrochloride oral tablet, Aurobindo
0.125 mg, 90 count (NDC 65862-0604-90) - discontinued
0.125 mg, 1000 count (NDC 65862-0604-99) - discontinued
0.25 mg, 90 count (NDC 65862-0605-90) - discontinued
0.25 mg, 1000 count (NDC 65862-0605-99) - discontinued
0.5 mg, 90 count (NDC 65862-0606-90) - discontinued
0.5 mg, 1000 count (NDC 65862-0606-99) - discontinued
0.75 mg, 90 count (NDC 65862-0607-90) - discontinued
0.75 mg, 1000 count (NDC 65862-0607-99) - discontinued
1 mg, 90 count (NDC 65862-0608-90) - discontinued
1 mg, 1000 count (NDC 65862-0608-99) - discontinued
1.5 mg, 90 count (NDC 65862-0609-90) - discontinued
1.5 mg, 1000 count (NDC 65862-0609-99) - discontinued

Pramipexole Dihydrochloride oral tablet, Mylan
0.125 mg, 90 count (NDC 00378-1704-77) - discontinued
0.125 mg, 500 count (NDC 00378-1704-05) - discontinued
0.25 mg, 90 count (NDC 00378-1705-77) - discontinued

0.25 mg, 500 count (NDC 00378-1705-05) - discontinued
0.5 mg, 90 count (NDC 00378-1707-77) - discontinued
0.5 mg, 500 count (NDC 00378-1707-05) - discontinued
0.75 mg, 90 count (NDC 00378-1713-77) - discontinued
1 mg, 90 count (NDC 00378-1711-77) - discontinued
1 mg, 500 count (NDC 00378-1711-05) - discontinued
1.5 mg, 90 count (NDC 00378-1712-77) - discontinued
1.5 mg, 500 count (NDC 00378-1712-05) - discontinued


Pramipexole Dihydrochloride oral tablet, Sandoz
0.125 mg, 90 count (NDC 00781-5248-92) - discontinued
0.25 mg, 90 count (NDC 00781-5249-92) - discontinued
0.5 mg, 90 count (NDC 00781-5250-92) - discontinued
0.75 mg, 90 count (NDC 00781-5281-92) - discontinued
1 mg, 90 count (NDC 00781-5251-92) - discontinued
1.5 mg, 90 count (NDC 00781-5252-92) - discontinued

Reason for the Shortage

Aurobindo, Mylan, and Sandoz have discontinued pramipexole tablets.

Available Products

Mirapex oral tablet, Boehringer Ingelheim
0.125 mg, 90 count (NDC 00597-0183-90)
0.25 mg, 90 count (NDC 00597-0184-90)
0.25 mg, unit-dose 100 count (NDC 00597-0184-61)
0.5 mg, 90 count (NDC 00597-0185-90)
0.5 mg, 90 count (NDC 00597-0185-61)
0.75 mg, 90 count (NDC 00597-0101-90)
1 mg, 90 count (NDC 00597-0190-90)
1 mg, unit-dose 100 count (NDC 00597-0190-61)
1.5 mg, 90 count (NDC 00597-0191-90)
1.5 mg, unit-dose 100 count (NDC 00597-0191-61)
 
Pramipexole Dihydrochloride oral tablet, Glenmark
0.125 mg, 90 count (NDC 68462-0330-90)
0.25 mg, 90 count (NDC 68462-0331-90)
0.5 mg, 90 count (NDC 68462-0332-90)
1 mg, 90 count (NDC 68462-0333-90)
1.5 mg, 90 count (NDC 68462-0334-90)
 
Pramipexole Dihydrochloride oral tablet, Torrent
0.125 mg, 90 count (NDC 13668-0091-90)
0.125 mg, 500 count (NDC 13668-0091-05)
0.25 mg, 90 count (NDC 13668-0092-90)
0.25 mg, 500 count (NDC 13668-0092-05)
0.5 mg, 90 count (NDC 13668-0093-90)
0.5 mg, 500 count (NDC 13668-0093-05)
0.75 mg, 90 count (NDC 13668-0184-90)
0.75 mg, 500 count (NDC 13668-0184-05)
1 mg, 90 count (NDC 13668-0094-90)
1 mg, 500 count (NDC 13668-0094-05)
1.5 mg, 90 count (NDC 13668-0095-90)
1.5 mg, 500 count (NDC 13668-0095-05)

Pramipexole Dihydrochloride oral tablet, Zydus
0.125 mg, 90 count (NDC 68382-0196-16)
0.125 mg, 1000 count (NDC 68382-0196-10)
0.25 mg, 90 count (NDC 68382-0197-16)
0.25 mg, 1000 count (NDC 68382-0197-10)
0.5 mg, 90 count (NDC 68382-0198-16)
0.5 mg, 1000 count (NDC 68382-0198-10)
1 mg, 90 count (NDC 68382-0199-16)
1 mg, 1000 count (NDC 68382-0199-10)
1.5 mg, 90 count (NDC 68382-0200-16)
1.5 mg, 1000 count (NDC 68382-0200-10)

Estimated Resupply Dates

All marketed presentations are available.

Related Shortages

Updated

March 4, 2016; December 23, November 12, October 13, September 30 and 10, July 2, April 27, February 25, January 14 and 12, 2015; December 15, November 24 and 11, October 23 and 1, September 18, 2014, University of Utah, Drug Information Service. Copyright 2016, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
Advertisement
ASHP Product Listing